Last reviewed · How we verify
Epivir®, Retrovir® and Viramune® — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Epivir®, Retrovir® and Viramune® (Epivir®, Retrovir® and Viramune®) — Elim Pediatric Pharmaceuticals Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epivir®, Retrovir® and Viramune® TARGET | Epivir®, Retrovir® and Viramune® | Elim Pediatric Pharmaceuticals Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Epivir®, Retrovir® and Viramune® CI watch — RSS
- Epivir®, Retrovir® and Viramune® CI watch — Atom
- Epivir®, Retrovir® and Viramune® CI watch — JSON
- Epivir®, Retrovir® and Viramune® alone — RSS
Cite this brief
Drug Landscape (2026). Epivir®, Retrovir® and Viramune® — Competitive Intelligence Brief. https://druglandscape.com/ci/epivir-retrovir-and-viramune. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab